Devices for Inhaled Medications Sales

Devices for Inhaled Medications Sales Market Outlook

The global market for devices for inhaled medications is projected to reach approximately USD 40 billion by 2035, with a compound annual growth rate (CAGR) of around 7.5% during the forecast period of 2025 to 2035. This growth is primarily driven by an increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), along with a growing preference for non-invasive treatment options. Additionally, the rise in awareness regarding the benefits of inhaled medications, coupled with advancements in inhaler technology and design, has contributed significantly to market expansion. The increasing geriatric population and environmental factors leading to respiratory issues are also key factors enhancing the demand for these devices. Moreover, the global healthcare infrastructure is improving, leading to better accessibility and affordability of inhaled medications.

Growth Factor of the Market

Several key factors are contributing to the growth of the devices for inhaled medications market. First and foremost, the increasing incidence of respiratory disorders, including asthma and COPD, is a significant driver. The World Health Organization (WHO) estimates that by 2025, the number of individuals affected by asthma will reach 400 million globally. Furthermore, technological advancements in inhaler devices, such as smart inhalers equipped with Bluetooth connectivity, have made it easier for patients to manage their conditions effectively. These innovations not only enhance adherence to medication regimens but also improve health outcomes. Regulatory support from health authorities in various regions is another driving factor, as it fosters the development and approval of new inhalation devices. Additionally, growing awareness and education surrounding respiratory diseases have led to increased screening and diagnosis, translating to a higher demand for inhalation therapies. Lastly, favorable reimbursement policies are enhancing patient access to inhaled medications, further fueling market growth.

Key Highlights of the Market

• Projected global market size of approximately USD 40 billion by 2035.
• CAGR of about 7.5% during the forecast period 2025-2035.
• Increasing prevalence of respiratory diseases such as asthma and COPD.
• Technological advancements in inhaler design and functionality.
• Regulatory support fostering new product innovation.

By Product Type

Metered Dose Inhalers:

Metered Dose Inhalers (MDIs) remain one of the most widely used devices for delivering inhaled medications, accounting for a substantial portion of the market share. These inhalers utilize a pressurized canister to deliver a specific dose of medication with each actuation. The convenience of MDIs, along with their portability, makes them a preferred choice for many patients suffering from asthma and COPD. Moreover, MDIs are compatible with various formulations and offer rapid medication delivery, which is crucial during acute asthma attacks. Continuous innovations in MDI technology, such as the introduction of breath actuated inhalers, are enhancing their usability. Furthermore, their wide availability through various distribution channels, including pharmacies and hospitals, continues to drive their consumption.

Dry Powder Inhalers:

Dry Powder Inhalers (DPIs) are increasingly gaining popularity in the inhaled medications market due to their ease of use and effective delivery of medication. Unlike MDIs, DPIs require patients to inhale forcefully to activate the device and dispense the drug. This characteristic makes them advantageous for patients who may struggle to coordinate their breathing with the actuation of an MDI. DPIs are often preferred for long-term management of chronic respiratory conditions as they do not require propellants, which can be an advantage for environmentally conscious consumers. The growth of the DPI segment is also supported by ongoing innovations such as user-friendly designs and enhanced medication formulations that improve patient compliance and medication efficacy.

Nebulizers:

Nebulizers are devices that convert liquid medication into a fine mist, making it easier for patients to inhale the medication directly into their lungs. This method is particularly beneficial for patients with severe respiratory issues or young children who may not be able to use MDIs or DPIs effectively. The nebulizer market is witnessing growth due to the increasing demand for home healthcare solutions, as these devices can be used in the comfort of one's home. Moreover, portable nebulizers are becoming more popular, as they offer convenience for patients who require continuous treatment. As healthcare systems focus on improving patient outcomes, nebulizers are gaining traction as a viable option for aerosol therapy in treating respiratory conditions.

Inhalers with Spacer:

Inhalers with spacers are designed to improve the delivery of medication to the lungs by creating a space between the inhaler and the mouth. This design allows aerosolized medication to disperse in the chamber before inhalation, enhancing the effectiveness of the treatment, especially in pediatric and elderly patients who may have difficulty inhaling correctly. The increased awareness of the benefits of using spacers has led to their rising adoption among healthcare professionals. Furthermore, the combination of inhalers with spacers reduces the risk of side effects associated with improper inhalation techniques, which provides a more effective delivery method for patients.

Soft Mist Inhalers:

Soft Mist Inhalers (SMIs) are a newer category of inhalation devices that produce a slow-moving aerosol cloud, allowing for easier inhalation of the medication. These inhalers are gaining traction due to their unique delivery mechanism, which requires less forceful inhalation compared to MDIs and DPIs, making them particularly suitable for patients with severe respiratory limitations. SMIs are particularly effective for delivering anticholinergic medications and are often used in the management of COPD. The growing recognition of SMIs' efficacy in delivering medication has led to an increase in their adoption, thereby contributing to the overall market growth of inhaled medication devices.

By Application

Asthma:

The asthma segment is a dominant application area within the inhaled medications market, driven by the high prevalence of this chronic respiratory condition. As awareness of asthma management improves, patients and healthcare providers are increasingly utilizing inhalation devices as a first-line treatment option. Inhaled medications, particularly bronchodilators and corticosteroids, are essential for managing asthma symptoms and preventing exacerbations. The market for asthma-focused inhalers is expected to grow as new formulations and technologies emerge, enabling more effective symptom control and improved quality of life for patients. Additionally, educational initiatives aimed at enhancing patient adherence to medication regimens will further bolster the demand for inhaled devices in this segment.

Chronic Obstructive Pulmonary Disease:

Chronic Obstructive Pulmonary Disease (COPD) represents another significant application driving the devices for inhaled medications market. COPD affects millions of people worldwide and is characterized by airflow limitation that is not fully reversible. Inhalation therapy is critical for managing COPD symptoms, reducing exacerbations, and improving overall lung function. The availability of combination therapies, which include bronchodilators and steroids, is particularly beneficial for COPD patients, contributing to the growth of this segment. The increasing aging population, combined with the rising prevalence of smoking and environmental pollution, is likely to drive further demand for inhalers and nebulizers specifically designed for COPD management.

Cystic Fibrosis:

Cystic Fibrosis (CF) is a genetic disorder that significantly affects the respiratory system, leading to chronic respiratory infections and declining lung function. Patients with CF often require aggressive inhalation therapy to manage their condition effectively. The market for inhaled medications targeting CF is experiencing growth due to advances in drug formulations and delivery systems that improve medication efficacy. The approval of novel therapies, such as mucolytics and antibiotics specifically designed for inhalation, is enhancing treatment options for CF patients. The increasing focus on personalized medicine in this area is expected to drive the utilization of inhalation devices, thereby expanding this application segment within the overall market.

Allergic Rhinitis:

Allergic rhinitis is a common condition that affects millions of individuals, characterized by symptoms such as sneezing, runny nose, and nasal congestion due to allergens. Inhaled medications, particularly nasal sprays and antihistamines, are frequently used for symptom relief. The growth of this segment is driven by increasing allergen exposure, including pollen, dust mites, and pet dander, which is becoming more prevalent in urban environments. As consumer awareness of allergic rhinitis and its treatments grows, so does the demand for inhalation devices that offer quick and effective symptom relief. The development of user-friendly inhalation systems that provide precise dosing will further contribute to increased adoption in this segment.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of inhaled medication devices, particularly for patients requiring specialized care. Hospitals often have access to a wide range of inhalation devices and medication formulations, allowing them to provide tailored treatments for patients with complex respiratory conditions. The growing trend of hospital admissions for respiratory diseases has led to increased demand for inhalers and nebulizers within these settings. Moreover, the presence of clinical pharmacists in hospitals ensures the effective management of therapies, thereby enhancing patient adherence and outcomes. As the healthcare industry continues to evolve, hospital pharmacies are expected to remain a significant distribution channel for inhaled medications.

Retail Pharmacies:

Retail pharmacies represent a vital distribution channel for inhaled medications, providing patients with convenient access to various inhalation devices and formulations. The increasing reliance on retail pharmacies can be attributed to their widespread availability and the growing trend of self-medication. Patients often prefer to purchase inhalers from retail outlets due to the immediate availability of products and the ability to consult pharmacists for guidance. The competitive nature of the retail pharmacy market also promotes discounts and promotions, further driving sales. With the rising prevalence of respiratory diseases, the retail pharmacy segment is poised for continued growth as it meets the demand for inhaled medications effectively.

Online Stores:

The emergence of online stores as a distribution channel for inhaled medications has transformed the way patients access their medications. The convenience of purchasing inhalation devices from the comfort of one's home, coupled with the ability to easily compare prices and products, has made online shopping an attractive option for many consumers. Additionally, the COVID-19 pandemic has accelerated the shift towards e-commerce in the healthcare sector, leading to increased sales of inhaled medications through online platforms. As more patients seek the convenience of online shopping and telehealth services, the online store segment is expected to witness significant growth in the coming years, further enhancing the overall inhaled medications market.

Drug Stores:

Drug stores serve as another essential distribution channel for inhaled medications, facilitating patient access to various inhalation devices. These establishments typically stock a range of inhaled products, including MDIs, DPIs, nebulizers, and accessories, catering to the diverse needs of patients with respiratory conditions. Drug stores often have knowledgeable staff who can assist customers in selecting the appropriate device and provide guidance on proper usage. The growing focus on chronic disease management, along with the increasing prevalence of respiratory disorders, is driving the demand for inhalation devices in drug stores. As healthcare systems prioritize patient education and support, drug stores are expected to play a significant role in the distribution of inhaled medications.

By Ingredient Type

Bronchodilators:

Bronchodilators are a key ingredient type in inhaled medications, providing relief for patients suffering from bronchospasm associated with conditions like asthma and COPD. These medications work by relaxing the muscles in the airways, leading to improved airflow and easier breathing. The bronchodilator segment is witnessing growth due to the increasing prevalence of respiratory diseases that require effective bronchodilation for symptom management. Inhaled bronchodilators, in both short-acting and long-acting formulations, are vital components of asthma and COPD treatment protocols. As new bronchodilator formulations continue to emerge, offering enhanced efficacy and safety profiles, this segment is expected to expand significantly in the inhalation device market.

Steroids:

Steroids, specifically inhaled corticosteroids (ICS), are essential in the management of chronic respiratory diseases, particularly asthma and COPD. These medications reduce inflammation in the airways, thereby improving lung function and preventing exacerbations. The growing awareness of the importance of controlling airway inflammation has led to an increase in the prescription and use of inhaled steroids. The steroid segment is projected to grow as more patients and healthcare providers recognize the role of ICS in long-term disease management. Ongoing research and development efforts are focused on enhancing the delivery of inhaled steroids, resulting in improved outcomes for patients and further propelling this segment's growth.

Anticholinergics:

Anticholinergics are another critical ingredient type employed in inhaled medications, primarily used in the management of COPD. These medications work by blocking the action of acetylcholine, leading to bronchodilation and improved airflow. The anticholinergic segment is gaining traction due to the increasing diagnosis of COPD and the rising demand for effective treatment options. The availability of long-acting anticholinergics has broadened the therapeutic options for patients, making them an integral part of combination therapies for better management of respiratory conditions. The shift towards personalized medicine and tailored treatment plans is expected to further drive the growth of the anticholinergic segment in the inhalation devices market.

Combination Therapy:

Combination therapy, which involves the use of two or more active ingredients in a single inhalation device, is becoming increasingly popular in the management of respiratory diseases. This approach is particularly beneficial for patients with complex conditions such as asthma and COPD, as it simplifies the treatment regimen and improves adherence. The combination therapy segment is expected to experience substantial growth as healthcare providers prioritize multi-faceted treatment strategies to optimize patient outcomes. The development of new combination inhalers, tailored to individual patient needs, is also propelling this segment forward. As the understanding of respiratory pathophysiology advances, the demand for combination therapy inhalers is likely to increase significantly.

By Region

North America holds a significant market share in the devices for inhaled medications market, driven by a high prevalence of respiratory diseases such as asthma and COPD. The region's robust healthcare infrastructure, combined with increasing awareness of treatment options, supports the growth of inhalation devices. The North American market is projected to grow at a CAGR of 7.2% during the forecast period, fueled by ongoing innovations in device technology and regulatory support for new product introductions. Additionally, the rising aging population in this region contributes to the increasing demand for effective inhalation therapies, leading to a favorable environment for market expansion.

Europe is another prominent region in the inhaled medications market, with substantial growth attributed to the increasing prevalence of respiratory disorders and advancements in inhalation technology. The European market is characterized by a strong focus on research and development, resulting in the introduction of innovative inhalation devices. The market is expected to see significant growth due to supportive healthcare policies and a growing emphasis on preventive healthcare measures. Furthermore, the increasing adoption of smart inhalers and connected devices in Europe is anticipated to enhance patient adherence and improve overall health outcomes, thereby positively impacting the regional market.

Opportunities

The devices for inhaled medications market is poised for substantial growth, presenting numerous opportunities for stakeholders. One of the most promising opportunities lies in the development of smart inhalers equipped with digital health technology. These devices can track medication usage, provide reminders, and allow for better communication between patients and healthcare providers. As chronic respiratory diseases are often managed through long-term treatment plans, smart inhalers can significantly enhance patient adherence and engagement. The integration of telemedicine and remote monitoring in respiratory care further strengthens the potential of smart inhalers, making them an attractive proposition for pharmaceutical companies and technology developers alike. Additionally, ongoing research into new formulations and delivery methods can lead to enhanced efficacy and improved patient outcomes, expanding the market for inhaled medications.

Another area of opportunity exists within emerging markets, where the demand for inhalation devices is on the rise due to increasing urbanization, changing lifestyles, and a growing awareness of respiratory health. As more people in these regions are diagnosed with respiratory conditions, there is a pressing need for effective treatment solutions. Companies that can successfully navigate the regulatory landscape and establish distribution channels in emerging markets stand to gain a competitive edge. Furthermore, strategic partnerships and collaborations with local healthcare providers can facilitate market entry and enhance product distribution. The focus on affordable healthcare solutions in these regions also presents a chance for companies to develop cost-effective inhalation devices that cater to the needs of the population, thereby driving growth in the global inhaled medications market.

Threats

Despite the promising growth prospects for the devices for inhaled medications market, several threats could hinder market expansion. One of the most significant threats is the increasing competition among manufacturers, which could lead to price wars and reduced profit margins. As more companies enter the inhalation device market, the focus on innovation and quality must remain paramount to differentiate products. Moreover, product recalls and safety concerns related to inhalation devices can pose a significant risk to companies, impacting brand reputation and customer trust. Regulatory hurdles also represent a challenge, as navigating the complex approval processes for new inhalation devices can be time-consuming and costly. These factors combined may create an environment of uncertainty for companies operating in the inhaled medications space.

Additionally, the rising awareness of alternative therapies may pose a restraining factor to the inhalation device market. Patients are increasingly exploring complementary and alternative medicine options, which may affect their reliance on conventional inhaled medications. Furthermore, the growing trend toward personalized medicine is leading to a shift in treatment paradigms, and companies that fail to adapt to these changes may find themselves at a disadvantage. It's essential for stakeholders in the inhaled medications market to stay informed about evolving patient preferences and consider integrating alternative therapies into their product offerings. Fostering collaboration with healthcare providers and investing in patient education are crucial strategies that can help mitigate these threats and promote sustained growth in this dynamic market.

Competitor Outlook

• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Sunovion Pharmaceuticals Inc.
• Chiesi Farmaceutici S.p.A.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Roche Holding AG
• Sanofi S.A.
• Baxter International Inc.
• Viatris Inc.

The competitive landscape of the devices for inhaled medications market is characterized by a diverse range of players, from large multinational corporations to specialized companies focusing exclusively on respiratory products. Leading pharmaceutical companies, such as GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim, dominate the market with their extensive product portfolios, strong research and development capabilities, and robust distribution networks. These companies are actively investing in innovative inhalation technologies, such as smart inhalers and combination therapies, to enhance the effectiveness and convenience of their products. Additionally, partnerships with healthcare providers and ongoing clinical trials to assess new formulations and delivery methods are critical strategies employed by these industry leaders to maintain their competitive edge in the market.

Smaller companies and niche players also play a vital role in the inhalation device market, often focusing on specific therapeutic areas or innovative delivery methods. For instance, companies like Sunovion Pharmaceuticals and Chiesi Farmaceutici are known for their specialized products targeting specific respiratory conditions. These companies leverage their agility and ability to quickly adapt to market trends to capture niche segments effectively. Emerging players are also exploring opportunities in the development of personalized inhalation therapies and novel delivery systems, which are becoming increasingly relevant in the evolving healthcare landscape. As the demand for inhaled medications continues to grow, strategic collaborations, mergers, and acquisitions will likely shape the competitive dynamics of this market. In summary, the devices for inhaled medications market presents a vibrant and dynamic competitive landscape, with opportunities for both established companies and emerging players to thrive. The focus on innovation, patient-centric solutions, and effective distribution strategies will be key determinants of success in this evolving market. Continued investment in research and development and strategic partnerships will be essential for companies seeking to stay ahead in the race to provide effective inhalation therapies. The future of inhaled medications is bright, and the competitive landscape is expected to evolve further as companies respond to changing patient needs and emerging healthcare trends.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Mylan N.V.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Viatris Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Baxter International Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim GmbH
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hikma Pharmaceuticals PLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Chiesi Farmaceutici S.p.A.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sunovion Pharmaceuticals Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Devices for Inhaled Medications Sales Market, By Application
    • 6.1.1 Asthma
    • 6.1.2 Chronic Obstructive Pulmonary Disease
    • 6.1.3 Cystic Fibrosis
    • 6.1.4 Allergic Rhinitis
    • 6.1.5 Others
  • 6.2 Devices for Inhaled Medications Sales Market, By Product Type
    • 6.2.1 Metered Dose Inhalers
    • 6.2.2 Dry Powder Inhalers
    • 6.2.3 Nebulizers
    • 6.2.4 Inhalers with Spacer
    • 6.2.5 Soft Mist Inhalers
  • 6.3 Devices for Inhaled Medications Sales Market, By Ingredient Type
    • 6.3.1 Bronchodilators
    • 6.3.2 Steroids
    • 6.3.3 Anticholinergics
    • 6.3.4 Combination Therapy
    • 6.3.5 Others
  • 6.4 Devices for Inhaled Medications Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Stores
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Devices for Inhaled Medications Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Devices for Inhaled Medications Sales market is categorized based on

By Product Type

• Metered Dose Inhalers
• Dry Powder Inhalers
• Nebulizers
• Inhalers with Spacer
• Soft Mist Inhalers

By Application

• Asthma
• Chronic Obstructive Pulmonary Disease
• Cystic Fibrosis
• Allergic Rhinitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Drug Stores
• Others

By Ingredient Type

• Bronchodilators
• Steroids
• Anticholinergics
• Combination Therapy
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Sunovion Pharmaceuticals Inc.
• Chiesi Farmaceutici S.p.A.
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Roche Holding AG
• Sanofi S.A.
• Baxter International Inc.
• Viatris Inc.